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Abstract
Background: “Evergreening” refers to the numerous strategies whereby owners of pharmaceutical products use patent
laws and minor drug modifications to extend their monopoly privileges on the drug. We aimed to evaluate the impact
of evergreening through the case study of the antidepressant citalopram and its chiral switch form escitalopram by
evaluating treatment efficacy and acceptability for patients, as well as health insurance costs for society.
Methods: To assess efficacy and acceptability, we performed meta-analyses for efficacy and acceptability. We
compared direct evidence (meta-analysis of results of head-to-head trials) and indirect evidence (adjusted indirect
comparison of results of placebo-controlled trials). To assess health insurance costs, we analyzed individual
reimbursement data from a representative sample of the French National Health Insurance Inter-regime Information
System (SNIIR-AM) from 2003 to 2010, which allowed for projecting these results to the whole SNIIR-AM population (53
million people).
Results: In the meta-analysis of seven head-to-head trials (2,174 patients), efficacy was significantly better for
escitalopram than citalopram (combined odds ratio (OR) 1.60 (95% confidence interval 1.05 to 2.46)). However, for the
adjusted indirect comparison of 10 citalopram and 12 escitalopram placebo-controlled trials, 2,984 and 3,777 patients
respectively, efficacy was similar for the two drug forms (combined indirect OR 1.03 (0.82 to 1.30)). Because of the
discrepancy, we could not combine direct and indirect data (test of inconsistency, P = 0.07). A similar discrepancy was
found for treatment acceptability. The overall reimbursement cost burden for the citalopram, escitalopram and its
generic forms was 120.6 million Euros in 2010, with 96.8 million Euros for escitalopram.
Conclusions: The clinical benefit of escitalopram versus citalopram remains uncertain. In our case of evergreening,
escitalopram represented a substantially high proportion of the overall reimbursement cost burden as compared
with citalopram and the generic forms.
Keywords: Evergreening, Meta-analysis, Health Insurance Reimbursement, Escitalopram, Citalopram, Chiral switch,
French health information system, generic drugs
Introduction
Evergreening refers to owners of pharmaceutical pro-
ducts using numerous strategies, such as patent laws
and minor drug modifications, to extend their monopoly
privileges with their products [1-3]. Typically, these
strategies are developed before expiry of the patent of
an original drug, usually a high-revenue drug [4-6]. If
they succeed, they result in an extension of the patent
protection period or a new patent for a minimally modi-
fied version of the drug.
A consequence of evergreening is delayed entry of gen-
eric drugs into the market with extension of the original
drug patent or competition between the patent-protected
minimally modified version of the drug and generic
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drugs [7]. This situation might increase drug reimburse-
ment costs by keeping the cheaper generic versions com-
pletely or partly out of the market [8]. Pharmaceutical
companies defend evergreening practices and claim that
revised formulas benefit patients (for example, by
improving adherence) and the drug industry (for exam-
ple, by providing incentives for companies to engage in
incremental innovation) [9-11].
Minimal modifications used in evergreening include
use of a different salt or molecule as an additive to the
main drug components, change in formulation, modified
release or change in route of administration [12,13]. An
enantiomer patent is another form of evergreening
based on a chiral switch (that is, from a chiral drug
developed as a racemic mixture to a single enantiomer)
[14]. Single-enantiomer drugs represent more than 50%
of the top-selling 100 drugs worldwide [15].
A typical example of this strategy was the case of citalo-
pram/escitalopram, two antidepressants. The Lundbeck
company’s patent on citalopram has run out in many
countries [15]. The company launched a single-enantiomer
drug, escitalopram, before the patent on the original drug
expired and significantly increased its advertising cam-
paigns to promote the new form [16]. However, the clinical
superiority of escitalopram over citalopram is still debated
[15]. Moreover, previous evergreening’s societal burden
analyses, dedicated to other evergreening examples, were
based on projections of market shares and health insurance
reimbursement costs [4,17].
We aimed to evaluate the impact of evergreening citalo-
pram with the chiral switch form escitalopram on efficacy
and treatment acceptability for patients, as well as health
insurance costs for society.
Methods
We investigated the relative efficacy and acceptability of
citalopram and escitalopram by performing meta-analyses
for direct evidence (meta-analyses of results of head-to-
head trials) and indirect evidence (adjusted indirect com-
parison of results of placebo-controlled trials). Health
insurance costs were analyzed through reimbursement
data for citalopram, its generic forms and escitalopram
from the French national health insurance information
system.
Assessment of relative efficacy of escitalopram and
citalopram
Identification and selection of randomized controlled trials
We identified randomized controlled trials by systemati-
cally identifying reviews published from 2000 to 2011
and trial results published from 2011 to 2012 [18], see
Section 1, Additional file 1.
Eligible reviews assessed the efficacy of citalopram or
escitalopram in adults with major depression based on
randomized trials. We searched several bibliographical
databases for reviews published between January 2000
and March 2011, and four repositories of national health
technology agencies, as well as the FDA. See Section 1,
Additional file 1.
Eligible randomized trials assessed acute treatment effi-
cacy, which was defined as eight-week treatment efficacy
of citalopram versus escitalopram or citalopram and/or
escitalopram versus placebo in patients with major depres-
sion, see Section 1, Additional file 1 for detailed selection
criteria. First, we screened selected reviews and listed all
included trials. The eligibility of trials was assessed inde-
pendently by two reviewers, with disagreements resolved
by consensus. Then, we searched for trial results published
from March 2011 to February 2012 in MEDLINE and
EMBASE. Finally, we searched for trial results in databases
from Lundbeck and Forest registries [19,20]. We also con-
tacted Lundbeck/France for a list of clinical trials for the
two medications.
Outcome measures
We assessed acute treatment efficacy, which was defined
as eight-week treatment. When the depression outcome
was measured at several timepoints, we extracted outcome
data at eight weeks. If not reported, we extracted outcome
data for the closest time points, ranging from 4 to 12
weeks [21,22], see Sections 1 and 2, Additional file 1 for
details about data extraction. We used outcome data for
the Montgomery-Åsberg depression rating scale (MADRS)
and, if not reported, the Hamilton scale. Efficacy was
assessed by the proportion of responders in each treat-
ment group, defined as patients with a decrease in depres-
sion score from baseline to follow-up of at least 50%, see
Section 2, Additional file 1.
We assessed treatment acceptability by the proportion of
patients who did not drop out of the allocated treatment
during the short-term treatment period (completers), see
Section 2, Additional file 1. Data were extracted by two
reviewers independently. Disagreements were resolved by
discussion. If outcome data were available from FDA
reports and other sources, priority was given to FDA data,
because the FDA re-analyses of raw data from the sponsor
adhered to the pre-specified statistical methods in the trial
protocol [23].
Meta-analysis of head-to-head trials and adjusted indirect
comparisons of placebo-controlled trials
First, we performed a meta-analysis of head-to-head trials.
Then, we performed an adjusted indirect evaluation of the
relative efficacy of each treatment compared to placebo
using Bucher’s method [24]. The effect of treatment was
measured by odds ratios (ORs) and 95% confidence inter-
vals (95% CIs). Combined estimates were calculated by
fixed- and random-effects models. The two models always
showed similar results [25]. In cases of significant treat-
ment effect, we re-expressed the results in terms of
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number needed to treat (NNT). We computed the NNT
from the combined ORs and by considering low and high
response rates for the control group, defined as the lower
and upper bounds of the 95% CI for the combined
response rate across control groups in the meta-analysis.
We assessed heterogeneity of treatment effect estimates
across trials using the I² statistic. We assessed similarity
(whether citalopram and escitalopram placebo-controlled
trials were similar for moderators of relative treatment
effect) by comparing clinical and methodological charac-
teristics of randomized comparisons [26]. We assessed
inconsistency between the direct and adjusted indirect
estimate by the difference between the two estimates and
associated 95% CIs and tested whether it was statistically
significant [27].
We assessed small-study effects by funnel plots [28]. Sen-
sitivity analyses for direct and adjusted indirect compari-
sons involved re-analyzing data after excluding head-to-
head trials without comparable dosages and excluding pla-
cebo-controlled trials as soon as the treated group did not
receive defined daily dose (DDD) dosages, respectively. In
addition, sensitivity analyses were performed excluding
trials with imputed outcome data and trials of older adults
only.
Assessment of reimbursement costs for citalopram, its
generic drugs and escitalopram
To assess the reimbursement burden of the three drug
forms on the French general health insurance regimes, we
analyzed data from the French national health insurance
information system (Système National d’Information
Inter-Régimes de l’Assurance Maladie, SNIIR-AM).
Data sources
The SNIIR-AM contains anonymous and comprehensive
data on health spending reimbursements from 2003. In
2009, it covered 86% of the French population, approxi-
mately 53 million people. We used a random represen-
tative sample (1/97) of SNIIR-AM, the Echantillon
généraliste de bénéficiaires (EGB). In 2009, the EGB
consisted of about 500,000 beneficiaries [29,30]. We
searched the EGB database using French identifiers for
drug products for the three drug forms. We examined
all reimbursement claims for the drugs between January
2003 and December 2010, given that generic citalopram
was introduced in December 2003 and escitalopram was
introduced in June 2005 in France.
Reimbursement cost analysis
To illustrate changes in consumption pattern, we calcu-
lated the monthly number of reimbursements and
monthly consumption in DDD units for the three drug
forms. According to the World Health Organization, the
DDD is the assumed average maintenance dose per day
for a drug used for its main indication in adults. The DDD
is 20 mg for citalopram and 10 mg for escitalopram [31].
To illustrate the evolution of spending, we calculated the
total monthly reimbursement costs for the three drug
forms. For all data, we produced time series plots. Because
the EGB sample is representative of the SNIIR-AM popu-
lation, we projected our analyses by dividing all results by
the sampling fraction so that estimates reflected the whole
SNIIR-AM population [30].
Analyses involved use of Stata MP v10.0 (Stata Corp.,
College Station, TX, USA). A P < 0.05 was considered
statistically significant.
Results
Assessment of relative efficacy of citalopram and
escitalopram
Of 248 records, we selected 41 reviews (Figure 1). In addi-
tion, we identified four reports from health technology
assessment agencies. From the 45 selected reviews, we
identified 81 full-text reports concerning potentially eligi-
ble randomized clinical trials and we selected 22 eligible
randomized controlled trials (RCTs) (Figure 1). Search for
trials, from 2011 to 2012, yielded one additional eligible
trial [32]. No additional trial from manufacturer registries
or Lundbeck’s list of trials was identified.
For the 23 RCTs, 4 had published results only, 6 had
unpublished results only and 13 had both published and
unpublished results. The trials provided for 29 randomized
comparisons: 7 between citalopram and escitalopram, 12
between escitalopram and placebo and 10 between citalo-
pram and placebo; 3 trials provided a closed loop compari-
son of citalopram, escitalopram and placebo (See Sections
3 and 4, Additional file 1).
A total of 2,569, 2,412 and 2,376 participants were
allocated to escitalopram, citalopram and placebo,
respectively. Elderly patients were included in four
trials. Outcome assessment times ranged from 4 to 12
weeks. All trials were sponsored by pharmaceutical
companies, except one by the Chinese National Insti-
tute for Pharmaceutical Research, (See Section 5, Addi-
tional file 1).
Meta-analysis of head-to-head trials
Of seven identified head-to-head randomized compari-
sons, all showed the superiority of escitalopram over cita-
lopram except Ou 2011 [32]. Escitalopram was associated
with higher response as compared with citalopram (ran-
dom-effects model, combined OR 1.60 (95% CI 1.05 to
.46)) (See Section 8, Additional file 1). This combined
OR would translate to a NNT of 8.5 and 9.6 patients to
achieve an additional response with escitalopram com-
pared to citalopram, when the control response rate is
lower (47%) or higher (61%). Heterogeneity was consider-
able across trials (I² = 80%; τ² = 0.26), but mainly because
of one trial, Yevtushenko 2007, which showed outlying
results. The funnel plot of the seven comparisons did not
reveal asymmetry; see Section 9, Additional file 1.
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Concerning acceptability, the proportion of treatment
completers was greater with escitalopram than citalo-
pram (Section 10, Additional file 1). For escitalopram
versus citalopram, the random-effects combined OR was
1.27 (0.93 to 1.72), with moderate heterogeneity (I² =
26% and τ² = 0.04).
Adjusted indirect comparisons of placebo-controlled trials
For the two meta-analyses of placebo-controlled compar-
isons of citalopram (n = 10 trials) and escitalopram (n =
12), we found no substantial heterogeneity across trials
(I² = 0% and τ² = 0.00 for citalopram vs. placebo; I² =
27% and τ² = 0.02 for escitalopram vs. placebo), Section
6, Additional file 1. Patients and trial characteristics were
similar for the two sets of placebo-controlled trials, see
Section 6, Additional file 1.
The proportion of responders was significantly greater
with citalopram and escitalopram than placebo and the
two effect sizes were of similar magnitude. Random-effects
combined OR 1.50 (1.27 to 1.78) for citalopram and 1.55
(1.33 to 1.82) for escitalopram. From these estimates, the
adjusted indirect comparison OR for citalopram versus
escitalopram was 1.03 (0.82 to 1.30). We found a large
inconsistency between the direct and indirect estimates
(difference in log ORs 0.44, corresponding to a ratio of OR
of 1.55, P = 0.07, Figure 2. Consequently, we could not
combine the direct and indirect estimates in a network
meta-analysis. Moreover, we could not perform a NNT
analysis because of a lack of difference in efficacy between
citalopram and escitalopram.
For each set of placebo-controlled trials, we found no
evidence of small-study effect (See Section 12, Additional
file 1; Egger’s test P = 0.79 for citalopram vs. placebo and
P = 0.46 for escitalopram vs. placebo).
Concerning acceptability, the proportion of treatment
completers was lower with citalopram and escitalopram
than placebo, with similar effect sizes, see Section 13,
Additional file 1, the random-effects combined OR 0.91
(0.75 to 1.10) for citalopram and 0.89 (0.73 to 1.07) for
escitalopram. From these estimates, the adjusted indirect
comparison OR for escitalopram versus citalopram was
0.98 (0.75 to 1.28), with large inconsistency between the
direct and indirect estimates (difference in log ORs 0.26,
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corresponding to a ratio of OR of 1.30 (P = 0.21), Figure 2.
We found no important heterogeneity in the two sets of
trials (I² = 0% and τ² = 0.00 for citalopram vs. placebo; I² =
25% and τ² = 0.03 for escitalopram vs. placebo).
The sensitivity analyses of the direct and indirect com-
parisons after excluding trials without comparable
dosages, with imputed outcome data or of older adults
only gave results consistent with those from the primary
analyses (data not shown).
Assessment of reimbursement costs for citalopram, its
generic drugs and escitalopram
Sections 7 and 14, Additional file 1 show the evolution of
the number of claims for each drug form. The projected
results from the EGB sample showed a substantial decrease
in consumption of citalopram between 2004 (2.1 million
claims) and 2006 (0.7 million claims). This decrease was
accompanied by an increase of approximately twice the
claims for the generic forms of citalopram during the same
period. Moreover, the new revised-formula escitalopram
represented 40% of the market share in 2006 (1.7 million
claims) after it was introduced to the market in April 2005.
Between 2006 and 2011, claims for citalopram continued
to decrease, to a lesser extent, and that for the generic
forms continued to increase, to peak in 2008, which was
followed by a slight decrease up to 2010. However, escitalo-
pram claims grew even more steeply towards the end of
2010, reaching 5.4 million claims. By the end of 2010,
escitalopram consumption had exceeded that of citalopram
and its generic forms combined (5.4 million claims for esci-
talopram vs. 0.2 and 1.7 million for citalopram and its gen-
eric forms, respectively) (Sections 7, 16 and 17, Additional
file 1).
Consumption in DDD units showed changes similar to
reimbursement results; for citalopram consumption, the
DDD units decreased from 73.9 million in 2004 to 7.6 mil-
lion in 2010, whereas for escitalopram, the units increased
from 15.7 million in 2005 to 193.9 million in 2010. For
generic forms of citalopram, the DDD units were 55.2 mil-
lion in 2005 and slightly increased to 58.8 million in 2010
(Sections 7 and 15, Additional file 1).
Reimbursement costs reflected the trends in consump-
tion (Figure 3; Section 7, Additional file 1). The total
monthly cost for the drugs was 5.6 million Euros when the
generic forms were introduced into the market. Although
the total monthly cost slightly decreased to 5.2 million
Euros when escitalopram was introduced into the French
market, in May 2005, the monthly cost reached 6.1 million
Euros a year subsequently (Figure 4). The cost burden of
escitalopram continued to increase, to reach 96.8 million
Euros in 2010, as compared with citalopram, 4.4 million
Euros (Figure 3). For the generic forms of citalopram, the
cost was >20 million Euros from 2005 to 2010. Moreover,
the reimbursement cost for escitalopram exceeded that of
citalopram and its generic forms combined (Figure 5).
Overall, the health cost burden of the three drug forms
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Figure 2 Direct and indirect comparisons of escitalopram and citalopram for efficacy and acceptability.
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reached 120.6 million Euros in 2010 (see Figure 5 and Sec-
tion 17, Additional file 1).
Discussion
We performed a large-scale systematic review to evaluate
the impact of evergreening of citalopram with the chiral
switch form escitalopram on efficacy, treatment acceptabil-
ity and health insurance costs. We found substantial discre-
pancy between the direct and indirect comparisons of
citalopram and escitalopram for short-term treatment effi-
cacy and acceptability. The direct comparison showed clini-
cal superiority of escitalopram over citalopram, but the
indirect comparison showed no evidence of difference
between the two. Our analysis of reimbursement costs for a
large representative sample of French health insurance ben-
eficiaries, showed that escitalopram took a large share of
the market, with citalopram substantially lower. The gen-
eric forms of citalopram started to gain an expected share
of the market, but the uptake was suppressed by
escitalopram competition. Moreover, escitalopram con-
sumption overcame citalopram and its generic forms
combined.
Network meta-analysis can be used to combine direct
and indirect estimates of efficacy or acceptability. The ana-
lysis borrows strength from all the available evidence and
increases statistical power and precision of estimates.
However, we could not perform such a network meta-ana-
lysis because of the observed discrepancy between direct
and indirect evidence. A possible explanation for the dis-
crepancy is dose difference among trials; however, sensitiv-
ity analysis for comparable dosages showed consistent
results. Another possible explanation could be bias in the
direct comparison or the indirect comparison [27,31].
Head-to-head trials are usually considered the gold stan-
dard. However, such trials may favor the sponsored treat-
ment [33,34] or the newest treatment [35-37]. In our
analysis, most head-to-head trials, except two, were spon-
sored by the manufacturer (Lundbeck/Forest Lab). One of
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the two trials was sponsored by Arbacom, a Russian com-
pany with potential conflict of interest with the Danish
manufacturer Lundbeck [38]. The trial results contained
outlying results, with strong superiority of escitalopram
over citalopram. The second trial was an institutional
funded trial [32], and did not find any evidence of differ-
ence between the two drugs. Escitalopram was superior to
citalopram in a network multiple-drug treatments meta-
analysis of efficacy without placebo controlled trials [22].
However, citalopram was superior to escitalopram, with a
statistical non-significance, in an extensive multiple-drug
treatments meta-analysis that considered the entire net-
work of second-generation antidepressant drugs and
including placebo-controlled trials [21].
Our indirect comparison may have been biased. For
instance, the characteristics of citalopram and escitalo-
pram placebo-controlled trials may have greatly differed,
which would have invalidated the adjusted indirect com-
parison. However, we found no evidence of unequal distri-
bution of potential treatment effect modifiers. Placebo-
controlled trials may have exhibited reporting bias.
Nevertheless, this bias is unlikely because as compared
with active comparator trials, placebo-controlled trials are
frequently registered with the FDA, which is considered a
gold standard for placebo-controlled trials in the antide-
pressant field [39] and when we searched the FDA data-
base, we identified five trials with unpublished data. As
well, the indirect comparison may have had low statistical
power [40]. However, we ensured a balance in the number
of included trials, with at least 10 randomized compari-
sons for both citalopram and escitalopram versus placebo.
Our study has some limitations. In the comparative
effectiveness analysis, we assessed treatment acceptabil-
ity only and did not assess safety outcomes [21,22]. Our
findings could not be generalized to other patent-
extended medications using chiral switch or other indi-
cations for citalopram/escitalopram usage. Second, we
examined the EGB sample [29], although the EGB is a
representative sample of the SNIIR-AM database [30].
The EGB data limited our analysis to begin with 2003,
so we were not able to look at the cost and consump-
tion trends earlier than 2003.
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Conclusions
We found strong uncertainty about the clinical benefits of
escitalopram over citalopram. Given the likelihood of spon-
sorship bias for head-to-head trials and the absence of
reporting bias for placebo-controlled trials [41], our
adjusted indirect comparison may be less biased than the
direct comparison. However, the market share of escitalo-
pram increased substantially and suppressed that of the
generic forms, which may have prevented a substantial cost
savings for health insurance, especially if we assumed pre-
scriptions shifted from escitalopram to generic citalopram.
Finally, as evergreened medications are typically launched
to the market before the patent of the original product
expires - in the expectation of generic competition - it
might be suitable to base the new product costs on the
estimated price of the generic form, rather than on the cur-
rent price of the originator. Moreover, health technology
assessment agencies could redefine product innovation to
reflect actual added benefits to patients and society. This
might effectively make the evergreened product less cost
effective and might help discourage this practice [42].
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